FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a report issued on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a “market perform” rating on shares of FibroGen in a research report on Wednesday.

FibroGen Price Performance

Shares of FGEN stock opened at $0.33 on Thursday. The business has a 50 day simple moving average of $0.36 and a 200 day simple moving average of $0.71. The firm has a market capitalization of $33.73 million, a price-to-earnings ratio of -0.27 and a beta of 0.72. FibroGen has a 12-month low of $0.18 and a 12-month high of $2.93.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same period last year, the business posted ($0.52) earnings per share. On average, equities analysts anticipate that FibroGen will post -1.12 EPS for the current fiscal year.

Institutional Trading of FibroGen

Institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC raised its position in FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after acquiring an additional 860,854 shares in the last quarter. AQR Capital Management LLC lifted its stake in FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after purchasing an additional 769,586 shares during the last quarter. Geode Capital Management LLC boosted its holdings in FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 32,884 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in FibroGen in the third quarter worth approximately $307,000. Finally, XTX Topco Ltd bought a new position in shares of FibroGen in the second quarter valued at $424,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.